AC Immune SA
ACIUAC Immune SA is a Swiss biopharmaceutical company focused on developing therapies for neurodegenerative and age-related diseases, including Alzheimer's and Parkinson's. It specializes in innovative platforms such as antibody and vaccine development to target misfolded proteins associated with these conditions.
Company News
AC Immune announced Phase 1 trial results showing its TDP-43 PET tracer ACI-19626 demonstrates significantly higher uptake in ALS patients compared to healthy controls, with detection in brain regions expected to accumulate TDP-43 pathology. The tracer showed good safety, tolerability, and suitable pharmacokinetic profile for brain imaging. Part ...
AC Immune and Eli Lilly have amended their 2018 collaboration agreement to advance new Tau Morphomer small molecule candidates for Alzheimer's disease treatment. AC Immune will receive a CHF10 million upfront payment and additional milestone payments, with IND-enabling studies expected to commence in H1 2026. The amendment reflects progress in ta...
AC Immune reported promising interim Phase 2 trial results for ACI-7104.056, an active immunotherapy targeting alpha-synuclein, showing potential to slow Parkinson's disease progression with a strong safety profile and 100% antibody responder rate.
AC Immune reported Q3 2025 financial results, highlighting a strategic refocus on high-value neurodegenerative disease assets, reducing workforce by 30%, and maintaining cash resources until Q3 2027. The company is progressing multiple clinical-stage immunotherapy and small molecule programs targeting neurodegenerative diseases.
AC Immune is reducing workforce by 30% to focus on late-stage clinical development of neurodegenerative disease therapies, extending cash runway to Q3 2027 and maintaining key clinical milestones.
